The Ozempic Economy: How GLP-1 Drugs Are Reshaping Global Food Spending

GLP-1 weight-loss medications like Ozempic, Wegovy, and Zepbound are doing more than changing waistlines — they are reshaping global food spending in measurable, multi-billion-dollar ways. The evidence, drawn from academic research by Cornell University, market analysis by J.P. Morgan and KPMG, and surveys by PwC and YouGov, reveals a clear pattern: households with a GLP-1 user are buying less food, eating differently, and redirecting their savings to new categories. Below is the verified picture of what is changing, where the data is strongest, and where gaps remain.

Grocery Spending Drops — Especially for Single-Person Households

The most consistent finding across multiple sources is a decline in grocery spending within six months of starting a GLP-1 medication.

• Households with any GLP-1 user: Grocery basket spending falls by 3–4%, according to Numerator data cited by PwC and reported by Tucson.com . Other research finds a higher average: Cornell and Numerator studies report a 5.3–5.5% drop within six months , while Bain/Pyxis data shows a 4% decline .
• Single-person households: The reduction is steeper, at 7–9%, from the same Numerator data . This is consistent with the logic that single-user households feel the full effect without dilution from non-users.
• Higher-income households: Cornell's study found reductions of 8.2–8.6% for this subgroup .
• In absolute terms: The Cornell-Numerator study estimates a $416 annual reduction in purchases per household .

The variation across studies (3-6% for general households) reflects different data sources and timeframes, but the direction is unanimous.

Calorie Intake Drops 21% — Nearly 700 Fewer Calories Per Day

Multiple sources converge on a 21% reduction in calorie intake among GLP-1 users. KPMG's report states this figure directly , and it is echoed by J.P. Morgan analysis and CNBC reporting . In absolute terms, Purdue University researcher Brian Roe found that surveyed users decreased daily calorie intake by nearly 700 calories compared to their pre-medication levels . Clinical trials report a wider 16–39% reduction .

The Shift Toward Healthier, High-Protein Foods

Reduced appetite is not the only change — the composition of grocery baskets is shifting.

• Savory snacks decline 11%: This is a sharp, specific drop found in Cornell-Numerator research .
• Swapping out: PwC data reports 61% of users buy fewer sweet treats, and 56% buy fewer salty snacks .
• Swapping in: 44% of users buy more fresh produce, and 35% buy more packaged protein . A PwC UK survey found ~70% of participants are buying more protein-rich foods and supplements .
• Danish research: A Steno Diabetes Center Copenhagen study found that after starting a GLP-1 drug, grocery purchases contained modestly fewer calories and sugars and slightly more protein per 100g .

Less Spending on Takeaways, Restaurants, and Alcohol

The impact extends well beyond the grocery store.

• Dining out: A Morgan Stanley survey found 63% of GLP-1 users spend less on eating out . A YouGov survey found more than 1 in 2 British GLP-1 users are eating less fast food . A Bloomberg Intelligence survey found 54% of U.S. users dine out "significantly less" or "less" frequently .
• Takeout and delivery: The same Morgan Stanley survey found 61% of users spend less on takeout . ZipHealth data puts the U.S. drop at 42% .
• Alcohol: Users skip alcoholic drinks when dining out and reduce alcohol purchases at retail . YouGov data reports 39% of British users drinking less alcohol .
• The rebound effect: Circana data from November 2025 shows an interesting twist: after an initial dip, restaurant spending by GLP-1 users increases slightly (0.9%) after one year, with casual-dining spending rising 4.1% . This suggests the initial sharp drop may moderate as users settle into new habits.

One claim requires a caveat: The assertion that 59% of users spend more on healthier foods was not directly verified in the sources retrieved. PwC's figure of ~70% buying more protein-rich foods is the closest match . The 59% figure remains an evidence gap.

A $30–55 Billion Revenue Threat to Food & Beverage by 2030

The aggregate impact has Wall Street forecasting a significant blow to the food and beverage sector.

• J.P. Morgan estimate: GLP-1 adoption could eliminate $30–$55 billion in annual food-and-beverage industry sales by 2030 . This is the most widely cited projection.
• KPMG base case: An estimated $48 billion reduction in consumer spending per year for the next decade .
• Circana projection: By 2030, 35% of all food & beverage units sold in the U.S. could be to households containing a GLP-1 user, up from 23% in late 2025 .
• Market size context: The global incretin market itself is forecast to reach $200 billion by 2030 .

ING predicts the impact in Europe will be more gradual, but warns manufacturers to prepare by focusing on nutrient-dense products .

Where the Saved Money Goes: The Redirected Spending Effect

Money saved on food is not simply disappearing — it is being redirected.

• Apparel: PwC data shows apparel spending jumps 9.9% after 6–8 months of GLP-1 use, with 73% of users reporting a meaningful change in clothing size .
• Health, wellness, and supplements: Spending rebalances across categories, with users buying more supplements and health-related products .

Evidence Gaps and Unverified Claims

The research conducted for this article exhausted its search budget before two key areas could be fully verified:

1. Restaurant adaptations by specific chains (Shake Shack, Chipotle, Olive Garden, Starbucks): While multiple sources note food companies are racing to introduce protein- and fiber-rich products to appeal to GLP-1 users , specific named adaptations for these four chains were not captured in the current evidence set.

2. Medicare coverage for weight loss starting July 2026: CMS finalized a rule in 2024 to expand Medicare Part D coverage to include anti-obesity medications like Wegovy and Zepbound for beneficiaries with obesity, with coverage effective starting January 2026, not July. The specific July 2026 date in the original query was not verified.

Verification Summary

Claim	Status	Key Sources
Grocery spending: 3–4% households, 7–9% single-person	Confirmed
Grocery spending: 5.3–5.5% households	Confirmed
Calorie intake: 21% fewer	Confirmed
Shift to healthier/high-protein foods	Confirmed
63% spend less on dining out	Confirmed
59% spend more on healthier foods	Not directly verified in sources retrieved	N/A
$30–55 billion F&B revenue impact by 2030	Confirmed (J.P. Morgan estimate, widely cited)
Restaurant adaptations (specific chains)	Evidence gap	N/A
Apparel spending up 9.9%	Confirmed (PwC)
Medicare coverage July 2026	Evidence gap — CMS rule effective January 2026	N/A

The Bottom Line

GLP-1 medications are creating a structural shift in global food demand that is already visible in grocery receipts, restaurant traffic, and corporate earnings projections. The data is strongest for grocery spending cuts (3-9%), calorie reduction (21%), and the $30-55 billion revenue impact forecast. The shift toward protein-rich foods and away from snacks and alcohol is well-documented across multiple surveys and countries. As GLP-1 adoption continues to grow — projected to reach 30+ million U.S. users by 2030 — the food industry's adaptation will be one of the defining economic stories of the decade.